Source: Annual Congress 2009 - EU Research Programmes: 1.GABRIEL 2.EvA 3.COPACETIC
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Ziegler-Heitbrock (Gauting, Germany). The EvA-Study: Markers of emphysema versus airway disease in COPD. Annual Congress 2009 - EU Research Programmes: 1.GABRIEL 2.EvA 3.COPACETIC

Member's Comments

No comment yet.

Related content which might interest you: Small airway inflammation in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001 The relationship between fibroblasts and airway structure in patients with asthma and chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 148s Year: 2001 Large airways remodeling in chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2008 - Pathophysiology of respiratory diseases Year: 2008 Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Systemic biomarkers Year: 2016 Relationship of airway dimensions with lung volumes in chronic obstrucive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 655s Year: 2006 Systemic and airway inflammation and the presence of emphysema in patients with COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Eosinophilic versus non-eosinophilic COPD cannot be distinguished by lung function nor CT determined emphysema or airway remodelling Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Airway inflammation markers in COPD Source: Annual Congress 2007 - Airway regulation, provocation and monitoring I Year: 2007 Annual FEV1 change : Post tuberculosis obstructive airway disease versus COPD Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016 Treatment of combined pulmonary fibrosis and emphysema Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Emphysematous phenotype is an independent predictor for frequent exacerbation of chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Phenotyping and monitoring asthma and COPD Year: 2014 Phenotypic markers of asthma and COPD at the tissue level Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Alveolar remodelling in COPD Source: Annual Congress 2006 - PG15 - Remodelling and repair in lung disease Year: 2006 Relationship of airway dimensions with airflow limitation or lung volumes in chronic obstructive pulmonary disease (COPD) Source: Eur Respir Rev 2006; 15: 197-199 Year: 2006 Airway inflammation in COPD: physiological outcome measures and induced sputum Source: Eur Respir J 2003; 21: 19S-28S Year: 2003 Airway inflammation persists after smoking cessation in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 249s Year: 2001 Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 521s Year: 2004 Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Airway T-lymphocytes expressing IFN-γ are reduced in smokers with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 6s Year: 2002 Influence of systemic inflammation and hypoxaemia on bone metabolism in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD diagnosis Year: 2013